Now and future:Strategies for diagnosis,prevention and therapies for Alzheimer’s disease  

现在与未来:阿尔茨海默病的诊断、预防和治疗策略

作　　者：Jiong Shi Jacques Touchon Lefkos T Middleton Mercé Boada Rovira Robert Vassar Bruno Vellas Yong Shen 施炯;Jacques Touchon;Lefkos T Middleton;Mercé Boada Rovira;Robert Vassar;Bruno Vellas;申勇

机构地区：[1]Department of Neurology,Institute on Aging and Brain Disorders,the First Affiliated Hospital of USTC,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230001,China [2]Neurodegenerative Disorder Research Center,Division of Life Sciences and Medicine,University of Science and Technology of China,Hefei 230026,China [3]Institute of Neuroscience,University Hospital Gui de Chauliac-Montpellier,Montpellier 34295,France [4]Ageing Epidemiology(AGE)Research,School of Public Health,Imperial College,London SW72AZ,UK [5]Centro de Investigación Biomédica en Red sobre,Enfermedades Neurodegenerativas(CIBERNED),Universitat International de Catalunya-Barcelona,Barcelona 08028,Spain [6]Department of Cell Biology,Medical School,Department of Neurology,Feinberg School of Medicine,Northwestern University,Chicago,IL 60611,USA [7]IHU HealthAge,WHO Collaborating Center for Frailty,Clinical&Geoscience Research and Geriatric Training,Toulouse University Hospital,INSERM UMR 1295,University Paul Sabatier,Toulouse 31000,France

出　　处：《Science Bulletin》2024年第23期3777-3784,共8页科学通报(英文版)

基　　金：supported by the National Key Plan for Scientific Research and Development of China(2020YFA0509304);the Chinese Academy of Sciences(XDB39000000);the National Natural Sciences Foundation of China(82030034 and 32121002);CAMS Innovation Fund for Medical Sciences(IFMS)(2021-I2M-C&T-B012);the Fundamental Research Funds for the Central Universities(YD9110002027 and YD9110002033);Anhui Provincial Key R&D Programs(202304295107020056);the Guangzhou Key Research Program on Brain Science(202007030008)。

摘　　要：After a number of failed drug studies on Alzheimer’s disease(AD)over the past decade,clinical trials of AD started to show encouraging results and were approved or pending approval for clinical use.However,controversies on the clinically meaningful benefits and risks of brain edema and microhemorrhages have reminded us to think further about monitoring treatment and developing new drug targets.The goal of this review is to find insights from clinical trials that aimed at two key pathological features of AD,i.e.,amyloid-β(Aβ)and tau protein,and to explore other targets such as anti-inflammation in AD.The complex pathophysiology of AD may require combination therapies rather than monotherapy.Throughout the course of AD,multiple pathways are disrupted,presenting a multitude of possible therapeutic targets for designing prevention and intervention for AD.

关 键 词：Alzheimer’s disease DEMENTIA AMYLOID TAU Biomarker Treatment 

分 类 号：R74[医药卫生—神经病学与精神病学]